SCHEMBL5151600

SCHEMBL5151600

COC(=O)c1cc(Cl)c(OCC2CCCN2C(=O)OC(C)(C)C)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 1/20 0.47
▸ USP30 Q70CQ3 1/20 0.47
▸ ALOX5AP P20292 3/20 0.45
▸ FEN1 P39748 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ F2RL3 Q96RI0 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ IL1B P01584 1/20 0.39
▸ P2RX7 Q99572 1/20 0.39
▸ APP P05067 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ HTR1D P28221 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1429354 0.88 ALDH1A1 (0.51) ALOX5APFEN1ALDH1A1F2RL3IL1B
SCHEMBL1429352 0.88 ALDH1A1 (0.51) ALOX5APFEN1ALDH1A1F2RL3IL1B
SCHEMBL5153102 0.86 UCHL1 (0.44) UCHL1USP30ALOX5APFEN1ALDH1A1
SCHEMBL5151622 0.82 NPC1 (0.47) UCHL1USP30ALOX5APFEN1NPC1
SCHEMBL29039401 0.80 CHRNB4 (0.47) UCHL1USP30ALOX5APFEN1
SCHEMBL26999489 0.80 CHRNB4 (0.47) UCHL1USP30ALOX5APFEN1
SCHEMBL29410752 0.80 CHRNB4 (0.47) UCHL1USP30ALOX5APFEN1
SCHEMBL5152035 0.80 LMNA (0.44) UCHL1USP30ALOX5APFEN1F2RL3
SCHEMBL4741479 0.80 CHRNB2 (0.47) UCHL1USP30ALOX5APFEN1F2RL3
SCHEMBL18013360 0.79 SCN9A (0.47) ALOX5APFEN1ALDH1A1APPHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 — — EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 — — EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 UCHL1 3675/4885USP30 4522/4885ALOX5AP 229/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 UCHL1 3469/4885USP30 4484/4885ALOX5AP 246/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 UCHL1 3482/4885USP30 4441/4885ALOX5AP 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback